Literature DB >> 6960001

HPLC, MS, and pharmacokinetics of melphalan, bisantrene and 13-cis retinoic acid.

T P Davis, Y M Peng, G E Goodman, D S Alberts.   

Abstract

High performance liquid chromatographic procedures are described for melphalan, bisantrene, and 13-cis retinoic acid, three important anticancer drugs in various stages of clinical development. The procedures require a rapid and simple sample clean-up followed by a 10-to 20-min chromatographic separation on a reversed-phase C18 column. Precisions are all less than 8% with recoveries greater than 80%. Mass spectrometry confirmation of each drug from patient sample separations is presented to provide unambiguous identification for valid pharmacokinetic parameter determination.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6960001     DOI: 10.1093/chromsci/20.11.511

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  4 in total

1.  A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma.

Authors:  H K Osterheld; E Musch; G E von Unruh; U Loos; H Rauschecker; B J Mühlenbruch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Pharmacokinetics of high-dose melphalan in children and adults.

Authors:  A Gouyette; O Hartmann; J L Pico
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  In vivo and in vitro metabolism of the new anticancer drug bisantrene.

Authors:  Y M Peng; D S Alberts; T P Davis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.

Authors:  M Zucchetti; M D'Incalci; Y Willems; F Cavalli; C Sessa
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.